| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/29/2008 | US7323173 Administration of phosphorylated Mammastatin having a molecular weight of 53 kDa or 49 kDa; the polypeptide is specifically reactive with monoclonal antibody 7G6 that is produced from hybridoma ATCC No. HB10152 |
| 01/29/2008 | US7323171 less immunosuppression than pre-existing therapies; anti-LFA-3 antibody homologs, anti-CD2 antibody homologs, soluble LFA-3 polypeptides, small molecules, e.g., carbohydrates, soluble CD2 polypeptides, CD2 or LFA-3 mimetic agents and derivatives |
| 01/29/2008 | US7323170 Anti-CD80 antibodies |
| 01/29/2008 | US7323169 Sustained release formulations |
| 01/29/2008 | US7323168 Immunotherapy for chronic myelocytic leukemia |
| 01/29/2008 | US7323167 Bonded to polyethylene glycol through a linking group, wherein the arginine deiminase is derived from Streptococcus, Borrelia, Giardia, Clostridium, Enterococcus, Lactobacillus, or Bacillus; improved tumoricidal activity; anticarcinogenic, antitumor, antimetastasis agents; melanoma |
| 01/29/2008 | US7323164 Can be administered in conjunction with radiation or chemotherapeutic agents. |
| 01/29/2008 | CA2505930C Use of botulinum toxin in the preparation of a pharmaceutical composition for treating urinary retention |
| 01/29/2008 | CA2471775C Targeted cytotoxic anthracycline analogs |
| 01/29/2008 | CA2438188C Modulated release particles for aerosol delivery |
| 01/29/2008 | CA2417455C Novel cyclooxygenase variants and methods of use |
| 01/29/2008 | CA2406367C Method for treating pain by peripheral administration of a neurotoxin |
| 01/29/2008 | CA2403349C Preparation of particles for inhalation |
| 01/29/2008 | CA2296720C Use of botulinum toxin in the preparation of a pharmaceutical composition for treating a prostate disorder in a mammal |
| 01/29/2008 | CA2295321C Isolated nona- and decapeptides which bind to hla molecules, and the use thereof |
| 01/29/2008 | CA2290446C Method and compositions for administering taxanes orally to human patients |
| 01/29/2008 | CA2284668C High beta-conglycinin products and their use |
| 01/29/2008 | CA2267651C Method of stimulating growth of melanocyte precursor cells with stem cell factor polypeptide |
| 01/29/2008 | CA2237721C Antineoplastic peptides |
| 01/29/2008 | CA2207078C Insulin derivatives with increased zinc binding |
| 01/29/2008 | CA2149776C Use of methioninase as an antitumor agent in anti-methionine chemotherapy |
| 01/29/2008 | CA2090650C Method of producing tissue factor pathway inhibitor |
| 01/27/2008 | CA2555516A1 Food additive for human and animal and uses thereof |
| 01/25/2008 | CA2553402A1 Compositions for inhibiting sema7a and vla-1 interaction and methods of using the same |
| 01/24/2008 | WO2008011633A2 Glycosylation of peptides via o-linked glycosylation sequences |
| 01/24/2008 | WO2008011624A2 Crystal structure of a receptor-ligand complex and methods of use |
| 01/24/2008 | WO2008011513A2 Compounds and methods of modulating angiogenesis |
| 01/24/2008 | WO2008011344A2 Disruption of programmed death-1 (pd-1) ligands to adjuvant adeno-associated virus vector vaccines |
| 01/24/2008 | WO2008011335A2 Metal binding compounds, metal binding compositions, and their uses |
| 01/24/2008 | WO2008011234A2 Recombinant host for producing l-asparaginase ii |
| 01/24/2008 | WO2008011204A2 Self-assembling protein hydrogel with bio-active protein |
| 01/24/2008 | WO2008011094A2 Cytokine induction of selectin ligands on cells |
| 01/24/2008 | WO2008011081A2 Wsx-1/p28 as a target for anti-inflammatory responses |
| 01/24/2008 | WO2008011006A2 Methods for treating pain and screening analgesic compounds |
| 01/24/2008 | WO2008010986A2 Methods of modulating angiogenesis |
| 01/24/2008 | WO2008010902A2 Regulation of tlr signaling by complement |
| 01/24/2008 | WO2008010472A1 Total enteral nutrition composition |
| 01/24/2008 | WO2008010341A1 Physiologically active polypeptide, polymer micelle having protein enclosed therein, and process for production of the polymer micelle |
| 01/24/2008 | WO2008010218A1 Peptides derived from human histone h2a and methods of use thereof |
| 01/24/2008 | WO2008010098A2 Identification, optimization and use of cryptic hla-b7 epitopes for immunotherapy |
| 01/24/2008 | WO2008010010A1 Identification, optimization and use of cryptic hla-b7 epitopes for immunotherapy |
| 01/24/2008 | WO2008009977A2 Methods and compositions for modulating socs3 |
| 01/24/2008 | WO2008009798A1 Composition based on d-glucosamine, on lactoferrin and on chondroitin sulphate for preventing and/or treating degenerative joint diseases |
| 01/24/2008 | WO2008009777A1 Hsv glycoproteins which induce chemokine-mediated cell migration |
| 01/24/2008 | WO2008009711A2 Use of soluble cd160 to suppress immunity |
| 01/24/2008 | WO2008009639A2 New indications for direct thrombin inhibitors |
| 01/24/2008 | WO2008009638A2 New indications for direct thrombin inhibitors in the cardiovascular field |
| 01/24/2008 | WO2008009635A2 Factor viia analogues with increased activity for treating thrombocytopenia |
| 01/24/2008 | WO2008009634A2 Factor viia analogues with increased activity for treating thrombocytopenia |
| 01/24/2008 | WO2008009470A1 Chiral compounds substituted with phosphonate ester or phosphonic acid |
| 01/24/2008 | WO2008009419A1 Human growth and differentiation factor gdf-5 |
| 01/24/2008 | WO2008009214A1 Polypeptide, nucleic acid molecule encoding it and their uses |
| 01/24/2008 | WO2008009062A1 Treatment for intimal hyperplasia and related conditions |
| 01/24/2008 | WO2007144492A3 Peptides with anti-proliferative activity |
| 01/24/2008 | WO2007143411A3 Use of a botulinum toxin for treating a urethral stricture |
| 01/24/2008 | WO2007143410A3 Use of a botulinum toxin for treating a urethral stricture |
| 01/24/2008 | WO2007139921A3 N-oxides of kappa opioid receptor peptides |
| 01/24/2008 | WO2007135172A3 Cladribine regimen for treating multiple sclerosis |
| 01/24/2008 | WO2007133711A3 Pharmaceutical compositions for vein irritating drugs |
| 01/24/2008 | WO2007115837A3 Combination of an anti-edb fibronectin domain antibody/ il2 fusion protein and a further small molecule |
| 01/24/2008 | WO2007112367A3 Potassium channel modulators and platelet procoagulant activity |
| 01/24/2008 | WO2007106385A3 Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment |
| 01/24/2008 | WO2007100684A3 Extracellular matrix/metastasis modifer genes for the prevention or inhibition of metastasis or growth of tumor and for characterization of tumor |
| 01/24/2008 | WO2007092537A3 Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same |
| 01/24/2008 | WO2007067618A3 The use of human stem cells and/or factors they produce to promote adult mammalian cardiac repair through cardiomyocyte cell division |
| 01/24/2008 | WO2007062023A3 Items containing a human pheromone component |
| 01/24/2008 | WO2007030375A3 Lysosomal acid lipase therapy for nafld and related diseases |
| 01/24/2008 | WO2007022531A3 Methods and compositions for the treatment of gastrointestinal disorders |
| 01/24/2008 | WO2007021661A3 Ligands of sh3 domains |
| 01/24/2008 | WO2006138026A8 Stable pharmaceutical compositions including motilin-like peptides |
| 01/24/2008 | WO2004103299A3 Compositions and methods for the treatment of cns injuries |
| 01/24/2008 | WO2004081188A3 Non-toxic membrane-translocating peptides |
| 01/24/2008 | WO2004069206A3 Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins |
| 01/24/2008 | US20080021208 Gemcitabine Prodrugs, Pharmaceutical Compositions and Uses Thereof |
| 01/24/2008 | US20080021202 For use in diagnosis and therapy of disease; screening for antagonists and agonists of Apop proteins |
| 01/24/2008 | US20080021196 Inhibitors of memapsin 2 and use thereof |
| 01/24/2008 | US20080021014 CYCLIC MALONAMIDES AS INHIBITORS OF Abeta PROTEIN PRODUCTION |
| 01/24/2008 | US20080020993 Regulation of cell proliferation and differentiation using topically applied nucleic acid molecules |
| 01/24/2008 | US20080020986 mimetics of the activity of the N-terminal portion of Smac/tertiary binding structure to IAPs, can be combined with chemotherapeutic agents like topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds; increased cell permeability, water solubility; antitumor agents |
| 01/24/2008 | US20080020985 Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof |
| 01/24/2008 | US20080020984 Crystal Structure of a Receptor-Ligand Complex and Methods of Use |
| 01/24/2008 | US20080020983 Peptides with antioxidant and antimicrobial properties |
| 01/24/2008 | US20080020982 Methods and compositions for treatment of atherosclerosis |
| 01/24/2008 | US20080020981 Non-nucleoside reverse transcriptase inhibitors |
| 01/24/2008 | US20080020980 Magnesium ammonium phosphate cement composition |
| 01/24/2008 | US20080020979 Peptides of Syndecan-1 For Inhibiting Angiogenesis |
| 01/24/2008 | US20080020978 CGRP peptide antagonists and conjugates |
| 01/24/2008 | US20080020977 Use of Fullerenes to Oxidize Reduced Redox Proteins |
| 01/24/2008 | US20080020976 Fragment of the C-terminal of dermcidin protein; protective skin treatment |
| 01/24/2008 | US20080020975 Galanin Receptors and Brain Injury |
| 01/24/2008 | US20080020974 Somatostatin and somatostatin agonists for treating insulin insensitivity and syndrome x |
| 01/24/2008 | US20080020973 Assays for identification of topoisomerase inhibitors |
| 01/24/2008 | US20080020972 Use of human chorionic gonadotropin orally for the treatment of overweight (obesity) associated with high blood tension, non-insulin-dependent diabetes, hypercholesterolemia, dyslipidemias and lipodystrophy |
| 01/24/2008 | US20080020971 Heptanoic acid derivatives as dipeptidyl peptidase inhibitors |
| 01/24/2008 | US20080020970 For promoting the release of growth hormone and of enhancing wound healing in a human or animal subject; for treating short stature, cachexia, wasting, type 2 diabetes, and poor circulation |
| 01/24/2008 | US20080020969 36 Human Secreted Proteins |
| 01/24/2008 | US20080020965 Oxidative damage and protease activity resistance; catalytic efficiency; deep vein thrombosis, disseminated intravascular coagulation, acute coronary syndrome; targeting protein, that interacts with tissue factor or the factor VIIa/tissue factor complex |
| 01/24/2008 | US20080020441 Passing a sample of minicells over a series of cross-flow filters, then through a dead-end filter; separating sample from contaminants to obtain a purified minicell preparation |
| 01/24/2008 | US20080020419 The use of saccharomyces cerevisiae erg4 mutants for expressing mammalian glucose transporter |
| 01/24/2008 | US20080020418 Cftr polypeptides, fragments thereof and methods of use to overcome biosynthetic misprocessing |